Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy.
Little is known of the changes in human immunodeficiency virus type 1 (HIV-1)-specific effector cytotoxic T lymphocytes (CTL) after potent antiretroviral therapy. Using HLA/peptide tetrameric complexes, we show that after starting treatment, there are early rapid fluctuations in the HIV-1-specific CTL response which last 1 to 2 weeks. These fluctuations are followed by an exponential decay (median half-life, 45 days) of HIV-1-specific CTL which continues while viremia remains undetectable. These data have implications for the immunological control of drug-resistant virus.
Ogg
G S
GS
Institute of Molecular Medicine, Nuffield Department of Medicine, Oxford OX3 9DS, United Kingdom.
Jin
X
X
Bonhoeffer
S
S
Moss
P
P
Nowak
M A
MA
Monard
S
S
Segal
J P
JP
Cao
Y
Y
Rowland-Jones
S L
SL
Hurley
A
A
Markowitz
M
M
Ho
D D
DD
McMichael
A J
AJ
Nixon
D F
DF
D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000032:analysis; D004359:Drug Therapy, Combination; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008562:Membrane Glycoproteins; D009244:NAD+ Nucleosidase / Q000032:analysis; D013602:T-Lymphocytes, Cytotoxic / Q000502:physiology*
D019380:Anti-HIV Agents; D015703:Antigens, CD; D000943:Antigens, Differentiation; D008562:Membrane Glycoproteins; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D009244:NAD+ Nucleosidase; D051997:ADP-ribosyl Cyclase 1